Organization
Trillium Therapeutics, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Trillium Therapeutics, Inc.
... TORONTO, ONTARIO--(Marketwired - Oct. 11, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the ...
... NASDAQ: TRIL TSX: TRIL Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL),a clinical stage immuno-oncology company developing innovative therapies for the ...
... Trillium Therapeutics Inc. has provided an update on its preclinical small molecule programs. Trillium's ...
... TORONTO, ONTARIO -- (Marketwired) -- 06/28/17 -- Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the ...
... and pharmaceutical companies, including a term as Chief Scientific Officer of Stem Cell Therapeutics (Trillium Therapeutics: NASDAQ). His experience includes over 10 years of drug ...
... Trillium Therapeutics Inc. has announced that based upon promising early evidence of anti-tumor activity ...
... Trillium Therapeutics Inc. has announced that it will present data on its TTI-621 (SIRPaFc) ...
... TORONTO, ONTARIO -- (Marketwired) -- 05/25/17 -- Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the ...
... - Encouraging preliminary clinical observations suggesting activity of TTI-621 both as a single agent and in combination therapy - Expanded pharmacology ...
... TORONTO, ONTARIO -- (Marketwired) -- 05/12/17 -- Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the ...
... TORONTO, ONTARIO--(Marketwired - May 12, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the ...
... Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the ...
... Inc, Taiwan Liposome Company Ltd, Theravectys SA, TRACON Pharmaceuticals Inc and Trillium Therapeutics Inc. The Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin ...
... Trillium Therapeutics Inc. (TSX:TRIL) (NASDAQ:TRIL) a clinical stage immuno-oncology company developing innovative therapies for ...
... Trillium Therapeutics Inc. has announced new pharmacology data from its ongoing Phase I a/b ...
... Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, has announced that it will present new ...
... Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, has initiated dosing in its second Phase ...
... CANADIAN INTRA-DAY STOCK REPORT Trillium Therapeutics Inc. (TSX:TR) hit a 52-week low of CAD8.08 earlier today for the ...
... CANADIAN INTRA-DAY STOCK REPORT Trillium Therapeutics Inc. (TSX:TR) extended its slide on Wednesday, shedding an additional 41.0c (or ...
... TORONTO, ONTARIO--(Marketwired - Nov. 29, 2016) - Trillium Therapeutics Inc. (TSX:TR)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the ...
... CANADIAN INTRA-DAY STOCK REPORT Trillium Therapeutics Inc. (TSX:TR) extended its gains on Wednesday, rising an additional 62.0c (or ...
... Company Limited, TG Therapeutics, Inc., Theravectys SA, TRACON Pharmaceuticals, Inc. and Trillium Therapeutics Inc. Order a purchase copy of this report @�http://www.reportsnreports.com/Purchase.aspx?name=682605. (This is a ...
... EDT ORIGINAL ANNOUNCEMENT [Text] TORONTO, ONTARIO--(Marketwired - May 18, 2016) - Trillium Therapeutics Inc. (TSX:TR) (NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for ...
... Trillium Therapeutics Inc. (TSX:TR) (NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤